DaVita Inc. with ticker code (DVA) have now 6 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The target price High/Low ranges between $120.00 and $90.00 suggesting an average analyst share price target price of $110.67. (at the time of writing). Now with the previous closing price of $111.61 this is indicating there is a potential downside of -.8%. It’s also worth noting that there is a 50 day moving average of $106.53 and the 200 day moving average is $98.27. The company has a market capitalization of 10.12B. The stock price for the company is currently $110.82 USD
The potential market cap would be $10,037,925,820 based on the market consensus.
The company has a dividend yield of 3.8%. Other points of data to note are a P/E ratio of 17.21, revenue per share of $131.29 and a 5.43% return on assets.
DaVita Inc. is a healthcare provider. The Company provides kidney care services in the United States. The Company’s operations are comprised of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (its ancillary services). The U.S. dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, and end-stage kidney disease (ESKD). Its services include outpatient hemodialysis services, hospital inpatient hemodialysis services, and home-based dialysis services. The ancillary services consist of integrated kidney care services, physician services, clinical research programs, and transplant software business, as well as international operations. The Company operates approximately 2,724 outpatient dialysis centers in the United States.
